- HeartBeam Inc BEAT announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended to detect heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office (USPTO).
- The company says that currently available wearables cannot provide a 12-lead ECG for heart attack detection, complex arrhythmia monitoring, or other cardiac disorders.
- HeartBeam's latest patent further expands on the company's anytime, anywhere capabilities.
- "The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection," said HeartBeam CEO and Founder Branislav Vajdic.
- Recently, HeartBeam shares jumped 75% after its patent for a 12-lead electrocardiogram patch monitor intended to detect acute coronary syndrome and cardiac arrhythmia, which the USPTO issued.
- Price Action: BEAT shares are down 1.40% at $3.65 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.